Biotech Values

[DewDiligence]

Originally, back in 2003 Momenta stated that NVS was to pay 100% of the development costs, but for some reason it must have been modified.

There was no modification to the agreement. NVS fronted 100% of the money for Lovenox development, as required by the 2003 agreement, and is entitled to recoup that money from the Lovenox net profits. The actual 2003 agreement (with numbers redacted) has been posted on this board, so there is no need to speculate about what it says.